Improved Diagnosis of Alpha-1 Antitrypsin Deficiency to Drive the Global Alpha-1 Antitrypsin Drugs Market Through 2020, Says Technavio

LONDON--()--Technavio analysts forecast the global alpha-1 antitrypsin drugs market to grow at a CAGR of close to more than 35% during the forecast period, according to their latest report.

The research study covers the present scenario and growth prospects of the global alpha-1 antitrypsin drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded drugs and off-label drugs used for the symptomatic treatment of diseases occurring due to alpha-1 antitrypsin deficiency and other disorders.

Technavio healthcare and life sciences analysts highlight the following four factors that are contributing to the growth of the global alpha-1 antitrypsin drugs market:

  • Improved diagnosis of alpha-1 antitrypsin deficiency (AATD)
  • Improving economic conditions
  • Novel product opportunities
  • High unmet needs

Improved diagnosis of AATD

AATD is difficult to diagnose in the majority of cases. The Alpha-1 Foundation reports that around 3% of all people who have diagnosed with COPD may have undetected AATD. The condition is misdiagnosed in most of the cases as asthma, smoking-related COPD, bronchitis, bronchiectasis, or other pulmonary conditions. These underlying conditions may confuse the clinical picture and thus lead to the difficulty in diagnosis. However, awareness programs conducted by various organizations worldwide will help in recognizing and differentiating the condition from other diseases. “For example, the Alpha-1 Foundation conducts support programs which include Alpha-1 Kids, Genetic Counselling Program, Caregivers Support Group, and education days at different locations throughout the US and an annual National Education Conference,” says Barath Palada, a lead analyst at Technavio for cardiovascular and metabolic disorders.

Improving economic conditions

Low-income groups cannot afford expensive plasma therapeutics that includes, alpha-1 antitrypsin drugs. Growing industrialization has resulted in improved global economic conditions and increased healthcare expenditure, enhancing the life expectancy of individuals. Developed countries are showing a willingness to use alpha-1 antitrypsin drugs because of the increase in income and the support provided by government and insurance companies in the form of reimbursement schemes for the treatment of life-threatening genetic diseases.

Novel product opportunities

A product opportunity exists when there is a need for better efficacy. New potential uses of alpha-1 antitrypsin drugs for the treatment of various diseases such as acute respiratory distress syndrome, diabetes, GVHD, and liver injury, are emerging in the market. Fractionation of plasma with new technologies yields new and improved plasma products, which show better efficacy in the treatment of diseases. For example, PlasmaTech SDF Process produces commercial quantities of alpha-1 antitrypsin, intravenous immune globulin, antihemophilic factor VIII, albumin, and ultra-orphan proteins like factor H, ceruloplasmin, C4 complement, and complement factor B. It is a simple two-stage process, which includes sodium citrate precipitation and diafiltration. This process increases the yield of alpha-1 antitrypsin up to 10 times. SDF technology can avoid the denaturation of the ultra-orphan protein products that occurs as a result of the Cohn's process.

High unmet needs

AATD is often undiagnosed or those with the condition are misdiagnosed for other indications. It is observed that a minimum of seven years will take for the final diagnosis of the condition from the time of appearance of first lung symptoms. The Alpha-1 Awareness UK has reported that less than 10% of the AATD patients are aware of their condition. This deficiency occurs in both children and adults with limited treatment options. The disease is considered as an orphan disease exhibiting substantial morbidity. The drugs are prepared from the fractionation of plasma obtained from blood banks. The amount of plasma required for the production of alpha-1 antitrypsin drugs is high, and this leads to the limited availability of the drugs in the market. “Organizations such as Alpha-1 Foundation are committed to finding a cure for AATD by collaborating with various pharmaceutical companies such as Alnylam Pharmaceuticals and Arrowhead Research,” says Barath.

Browse Related Reports:

Purchase these three reports for the price of one by becoming a Technavio subscriber. Subscribing to Technavio’s reports allows you to download any three reports per month for the price of one. Contact enquiry@technavio.com with your requirements and a link to our subscription platform.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com

Release Summary

Technavio analysts forecast the global alpha-1 antitrypsin drugs market to grow at a CAGR of close to more than 35% during the period 2016-2020.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com